Arrowstreet Capital’s Caris Life Sciences CAI Stock Holding History
Bought
Maintained
Sold
Other funds holding CAI
Arrowstreet Capital's CAI Position: Q3 2026 in Review
Arrowstreet Capital increased its Caris Life Sciences (CAI) stake by 57% in Q3 2026, buying an estimated $8.44M and bringing the position to 1,031,536 shares worth $31.6M. The position accounts for 0.01% of the portfolio, ranked #673.
Arrowstreet Capital first reported a position in CAI in Q1 2026 and has held it in 3 quarters since. 330 funds tracked by Wall St. Rank hold CAI as of Q3 2026.
- Arrowstreet Capital held 1,031,536 shares of Caris Life Sciences worth $31.6M as of Q3 2026.
- Arrowstreet Capital bought 375,892 Caris Life Sciences shares in Q3 2026, an estimated $8.44M.
- Caris Life Sciences made up 0.01% of Arrowstreet Capital's portfolio in Q3 2026, its #673 holding.
- Arrowstreet Capital first reported a position in Caris Life Sciences in Q1 2026 and has held it in 3 quarters since.
- 330 funds tracked by Wall St. Rank held Caris Life Sciences as of Q3 2026.
Based on Arrowstreet Capital's 13F filing for Q3 2026, filed 13 Nov 2026.